Challenges and Opportunities in Diabetes Research and Treatment joint with Obesity: A Multisystems Perspective Organizer(s): Domenico Accili, Masato Kasuga and Morris F. White Date: January 12 - 17, 2014
Location: Fairmont Hotel Vancouver, Vancouver, BC, CanadaType 2 diabetes affects more than 250 million people worldwide, and available therapeutic options for its treatment fall short of reversing its progressive course, let alone preventing it. This conference is focused on bringing together scientists from academia, government, and industry, to assess the state of medical discovery in areas that are likely to yield therapeutic advances for the prevention, treatment, and reversal of type 2 diabetes. The organizers have identified the following areas, among many deserving to be highlighted, for in-depth analyses and discussions: increasing energy dispersal through 'browning' of white fat; metabolic effects of bariatric surgery; hormonal of hepatic lipid and glucose metabolism; integration of omics-based findings to identify biomarkers of disease predisposition and outcomes; insulin signaling and impaired beta cell function; diabetes and cancer; circadian regulation of metabolism and predisposition to diabetes; mechanisms of insulin signaling in the heart and their relationship to heart disease; and emerging therapeutic concepts in counterregulatory systems. The pace of discovery has been especially brisk in these areas, and it's likely to yield exciting new information and therapeutic advances in the foreseeable future. The conference will act as a catalyst for further progress by bringing together leaders in the academic and pharmaceutical communities to present the latest developments in their research. Scholarship Deadline: October 4 2013 Discounted Abstract Deadline: October 4 2013 Abstract Deadline: October 29 2013 Discounted Registration Deadline: November 14 2013 We gratefully acknowledge additional support for this conference from:  We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
MedImmune
Amgen Inc.
We gratefully acknowledge the generous grant for this conference provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Grant No. 5R13DK084688-05 The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. |